Insider Selling: Kura Oncology (NASDAQ:KURA) Insider Sells $130,704.00 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Mollie Leoni sold 12,448 shares of the stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of $10.50, for a total value of $130,704.00. Following the sale, the insider directly owned 169,897 shares of the company’s stock, valued at approximately $1,783,918.50. The trade was a 6.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Mollie Leoni also recently made the following trade(s):

• On Tuesday, September 29th, Mollie Leoni sold 28,802 shares of Kura Oncology stock. The shares were sold at an average price of $10.75, for a total transaction of $309,621.50.

Kura Oncology Stock Down 0.6%

Kura Oncology stock opened at $10.65 on Friday. The stock has a market capitalization of $947.42 million, a PE ratio of -3.16 and a beta of 0.47. Kura Oncology, Inc. has a twelve month low of $7.36 and a twelve month high of $13.90. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The company has a 50 day moving average of $11.23 and a 200-day moving average of $10.19.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The company had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. On average, equities research analysts anticipate that Kura Oncology, Inc. will post -3.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

KURA has been the topic of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research report on Friday, July 17th. Wells Fargo & Company set a $24.00 price objective on Kura Oncology in a report on Thursday, June 4th. Wedbush lifted their target price on Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. Finally, Morgan Stanley set a $24.00 target price on Kura Oncology in a research note on Monday, August 24th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Kura Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $25.69.

More Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: JPMorgan initiated coverage of Kura Oncology with an “overweight” rating and a $30 price target, implying substantial upside from recent trading levels. The firm views Kura as a promising precision-cancer-medicine developer, particularly because of its menin-inhibitor platform and lead program, ziftomenib, for genetically defined acute myeloid leukemia. JPMorgan Kura Oncology rating article
• Positive Sentiment: CNBC highlighted JPMorgan’s view that KURA could nearly triple, reinforcing the potential valuation impact of successful clinical and regulatory execution. The bullish outlook is particularly important for a biotechnology stock trading below the average analyst target of approximately $25.40. CNBC Kura Oncology analyst outlook
• Neutral Sentiment: Kura’s financial position remains relatively liquid, with a reported quick ratio of 4.71 and current ratio of 4.73, but the company remains unprofitable and analysts expect a significant full-year loss. That means the stock’s valuation continues to depend heavily on clinical progress rather than current earnings.
• Negative Sentiment: Multiple insiders, including executives Kathleen Ford, Brian Powl, Mollie Leoni, Thomas Doyle and Teresa Bair, sold shares in late September and October 1. The reported transactions represent roughly 97,000 shares and more than $1 million in proceeds, creating a potential near-term overhang. The sales do not necessarily indicate deteriorating business prospects, since the insiders retained meaningful holdings, but they may weigh on investor confidence. Kura Oncology insider sales

Institutional Trading of Kura Oncology

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tidal Investments LLC acquired a new position in Kura Oncology during the second quarter valued at approximately $1,029,000. WINTON GROUP Ltd increased its position in shares of Kura Oncology by 26.2% during the 2nd quarter. WINTON GROUP Ltd now owns 13,000 shares of the company’s stock worth $143,000 after purchasing an additional 2,700 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Kura Oncology during the 2nd quarter worth approximately $159,000. IFP Advisors Inc raised its stake in shares of Kura Oncology by 136.5% during the 2nd quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock worth $28,000 after purchasing an additional 1,467 shares in the last quarter. Finally, Allworth Financial LP raised its stake in shares of Kura Oncology by 148.4% during the 2nd quarter. Allworth Financial LP now owns 10,326 shares of the company’s stock worth $113,000 after purchasing an additional 6,169 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.